Novartis receives FDA approval of Tafinlar + Mekinist for adjuvant treatment of BRAF V600-mutant melanoma Read more
AbbVie Submits Application to EMA for Investigational Treatment Risankizumab for Moderate to Severe Plaque Psoriasis Read more
Bavarian Nordic receives FDA Orphan Drug Designation for BN-Brachyury for the treatment of Chordoma Read more
Merck KGaA, Darmstadt, Germany to Develop Abituzumab in Metastatic Colorectal Cancer with SFJ Pharmaceuticals Group Read more